These findings indicated that PSMD8 can better reflect the prognosis of patients with ovarian serous carcinomas, and in patients with advanced FIGO stage and TP53 mutation, PSMD8 showed a more significant correlation with prognosis. The gene discussed is TP53; the disease is ovarian serous carcinoma.